Sinotherapeutics Inc. (SHA:688247)

Market Cap	4.89B
Revenue (ttm)	509.13M
Net Income (ttm)	125.29M
Shares Out	449.00M
EPS (ttm)	0.28
PE Ratio	38.63
Forward PE	n/a
Dividend	0.07 (0.68%)
Ex-Dividend Date	Jun 27, 2025

Volume	3,554,721
Average Volume	3,352,652
Open	10.96
Previous Close	10.93
Day's Range	10.81 - 11.05
52-Week Range	7.40 - 14.00
Beta	0.12
RSI	64.31
Earnings Date	Aug 23, 2025

About Sinotherapeutics

Sinotherapeutics Inc., a specialty pharmaceutical company, develops generic and formulation products in China. It offers posaconazole delayed-release tablets, ursodeoxycholic acid capsules, bupropion hydrochloride extended-release tablets, paroxetine extended-release tablets, sevelamer carbonate tablets, and propafenone hydrochloride extended-release capsules. The company provides CRO/CDMO services including pre-formulation study, formulation and process development, clinical sample manufacturing, NDA registration batch manufacturing, quality s...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2012
• Employees: 312
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688247

Financial Performance

In 2024, Sinotherapeutics's revenue was 511.62 million, an increase of 70.61% compared to the previous year's 299.87 million. Earnings were 127.70 million, an increase of 109.09%.